A 2026 animal study found that dapagliflozin, a diabetes drug, reduced liver fat by activating cellular energy-production pathways in mice with fatty liver disease. According to Gram Research analysis, the drug triggered a fasting-like metabolic state that improved mitochondrial function and prevented liver damage, though human trials are needed to confirm these results apply to people.
Researchers tested a diabetes drug called dapagliflozin on mice with fatty liver disease, a condition where fat builds up in the liver and damages it. According to Gram Research analysis, the drug reduced liver fat and improved how the liver’s energy-producing structures (mitochondria) work. The mice that received the drug also lost weight without losing muscle. These findings suggest dapagliflozin might help people with metabolic fatty liver disease, though human studies are still needed to confirm these results.
Key Statistics
A 2026 research article published in Naunyn-Schmiedeberg’s Archives of Pharmacology found that dapagliflozin significantly attenuated hepatic steatosis and improved mitochondrial bioenergetics in mice fed a high-fat diet combined with fructose water.
The study demonstrated that dapagliflozin-treated mice achieved weight loss and reduced adiposity while preserving muscle mass, a critical finding for potential therapeutic applications in metabolic fatty liver disease.
Research showed that dapagliflozin’s beneficial effects appeared mediated through activation of the SIRT1-PGC-1α-NRF1 signaling axis, suggesting a specific cellular mechanism for protecting mitochondrial function in fatty liver disease.
The Quick Take
- What they studied: Whether a diabetes medication called dapagliflozin could reduce fatty buildup in the liver and improve how liver cells produce energy
- Who participated: Laboratory mice (C57BL/6 strain) divided into groups: some ate normal food, others ate high-fat food with added sugar. This was an animal study, not human research.
- Key finding: Mice treated with dapagliflozin showed significant reduction in liver fat, better mitochondrial function, and weight loss without muscle loss compared to untreated mice with fatty liver disease
- What it means for you: This research is early-stage and only tested in mice. While promising, it suggests dapagliflozin might eventually help people with fatty liver disease, but human clinical trials are necessary before doctors could recommend it for this purpose
The Research Details
Scientists created fatty liver disease in mice by feeding them a high-fat diet combined with sugar water for 16 weeks. Starting at week 10, they gave some mice dapagliflozin (a drug already used for diabetes) while others received a placebo. The researchers measured liver fat using imaging, tested how well the mice’s bodies handled sugar, examined liver tissue under microscopes, and analyzed proteins that control energy production in cells.
This approach mimics how human fatty liver disease develops—through poor diet—making the mouse model relevant for understanding the disease. The researchers specifically looked at whether dapagliflozin triggered a ‘fasting-like’ state in the body, meaning the metabolism shifts as if the animal hadn’t eaten, which can help the liver heal.
The study measured multiple outcomes including body weight, liver fat content, muscle mass, mitochondrial health, and specific proteins involved in cellular energy production and stress response.
Fatty liver disease is a growing health problem with no proven medications. Understanding how dapagliflozin works at the cellular level—particularly through improving mitochondrial function—could lead to new treatments. This research bridges the gap between basic science and potential clinical applications by testing a mechanism that could be relevant to human disease.
This is a controlled laboratory study with clear experimental groups and multiple measurement methods, which strengthens reliability. However, it’s conducted only in mice, so results may not directly translate to humans. The study appears well-designed with appropriate controls and multiple outcome measures, but the lack of specified sample size details and the preliminary nature of animal research means caution is warranted before drawing human conclusions.
What the Results Show
Mice fed a high-fat diet with sugar developed fatty liver disease similar to the human condition. When treated with dapagliflozin, these mice showed substantial reduction in liver fat accumulation compared to untreated mice. The drug also preserved the structure and function of mitochondria—the cell’s energy factories—which are typically damaged in fatty liver disease.
The treated mice lost weight and reduced body fat without losing muscle mass, which is important because muscle loss is a concern with some weight-loss interventions. Liver cells also showed reduced signs of stress and damage. The researchers identified that these improvements appeared connected to activation of specific proteins (SIRT1, PGC-1α, and NRF1) that control mitochondrial health and energy production.
Glucose tolerance tests showed improved sugar metabolism in treated mice, suggesting the drug helped restore normal metabolic function. These improvements occurred without apparent negative side effects in the study period.
The study found that dapagliflozin appeared to trigger a metabolic state similar to fasting, where the body shifts to using stored energy more efficiently. This ‘fasting-mimicking’ effect may explain how the drug helps the liver recover. The preservation of mitochondrial structure at the ultrastructural level (visible under electron microscopes) indicates the drug protects cellular energy-producing machinery from damage.
Fatty liver disease has been difficult to treat with medications. Previous research suggested that improving mitochondrial function could help, but few drugs have shown this effect. This study adds to growing evidence that certain diabetes medications might have benefits beyond blood sugar control. The mechanism identified here—activation of the SIRT1-PGC-1α pathway—aligns with other research on cellular aging and metabolic health.
This research was conducted only in mice, and animal studies don’t always produce the same results in humans. The study didn’t specify the exact number of mice used in each group, making it harder to assess statistical power. The treatment period was relatively short (6 weeks of drug exposure), so long-term effects remain unknown. The study doesn’t compare dapagliflozin to other potential treatments for fatty liver disease. Additionally, mice and humans have different metabolisms, so the drug’s effectiveness and safety in people requires separate human clinical trials.
The Bottom Line
Based on this animal research, dapagliflozin shows potential as a treatment for metabolic fatty liver disease, but this is preliminary evidence. Current confidence level: Low to Moderate (animal study only). Do not use dapagliflozin for fatty liver disease outside of clinical trials without consulting your doctor. If you have fatty liver disease, discuss current evidence-based treatments with your healthcare provider, which may include lifestyle changes like diet and exercise.
People with metabolic fatty liver disease or those at risk (obesity, type 2 diabetes, metabolic syndrome) should follow this research. Healthcare providers treating liver disease should monitor developments. This is less immediately relevant to people without liver disease. Those already taking dapagliflozin for diabetes should not change their treatment based on this single animal study.
If dapagliflozin moves to human trials, it typically takes 3-7 years for clinical research to determine safety and effectiveness. Any potential new use for fatty liver disease would require FDA approval, which could take several additional years. Realistic timeline for clinical availability: 5-10 years at minimum.
Frequently Asked Questions
Can I take dapagliflozin to treat fatty liver disease?
Not yet. This 2026 study only tested dapagliflozin in mice with fatty liver disease. While results are promising, human clinical trials are required before doctors can recommend it for this condition. Discuss current treatment options with your healthcare provider.
What is metabolic fatty liver disease and why is it hard to treat?
Metabolic fatty liver disease occurs when fat accumulates in liver cells, damaging the mitochondria (energy factories). It’s difficult to treat because most medications don’t specifically fix mitochondrial damage. This research suggests dapagliflozin might address this underlying problem.
How does dapagliflozin help the liver in this study?
The drug triggered a fasting-like metabolic state that activated proteins controlling mitochondrial health and energy production. This protected liver cells from damage and reduced fat accumulation, though the exact mechanism in humans remains to be determined.
When will dapagliflozin be available for fatty liver disease treatment?
If human clinical trials begin soon, it could take 5-10 years minimum before potential FDA approval for fatty liver disease. Currently, it’s only approved for diabetes and heart conditions. Lifestyle changes remain the most proven treatment available now.
Are there any proven treatments for fatty liver disease right now?
Weight loss through diet and exercise are the most effective current treatments, reducing liver fat by 30-90% depending on weight loss amount. Some medications help manage related conditions like diabetes. Talk to your doctor about personalized treatment options.
Want to Apply This Research?
- If you have fatty liver disease, track liver enzyme levels (ALT and AST) from blood tests every 3 months, along with weight and waist circumference monthly. Note any changes in energy levels and digestion.
- Use the app to log daily diet choices focusing on reducing high-fat and high-sugar foods, which are the primary drivers of fatty liver disease. Set reminders for consistent exercise (150 minutes weekly), which research shows helps reverse fatty liver disease.
- Create a dashboard tracking liver health markers from doctor visits, weight trends, and dietary adherence. Set quarterly check-in reminders to review progress with your healthcare provider and adjust lifestyle interventions as needed.
This article discusses preliminary animal research and should not be interpreted as medical advice. Dapagliflozin is not currently approved for treating fatty liver disease. Do not start, stop, or change any medications without consulting your healthcare provider. If you have fatty liver disease or suspect you might, work with a qualified physician to develop an appropriate treatment plan. This research represents early-stage findings that require human clinical trials before clinical application. Always consult your doctor before making health decisions based on research studies.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.